NCT02450656View on ClinicalTrials.gov

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

May 31, 2019

Study Completion Date

December 31, 2019

Conditions
Colorectal NeoplasmsGastrointestinal NeoplasmsPancreatic NeoplasmsCarcinoma, Non-Small-Cell Lung
Interventions
DRUG

Afatinib

Tablet

DRUG

Selumetinib

Capsule

DRUG

Docetaxel

Trial Locations (2)

6525GA

RECRUITING

UMC St. Radboud Nijmegen, Nijmegen

1066CX

RECRUITING

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Boehringer Ingelheim

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER